Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition

Abstract Introduction An extensive array of medicinal plants has undergone investigation, underscoring the imperative for the continued screening of natural inhibitors with the potential to target cancer metabolism. The current research endeavor was directed toward evaluating the chemotherapeutic ef...

Full description

Saved in:
Bibliographic Details
Main Authors: Flama Monteiro, Vijith Vittal Shetty, Ranjitha Acharaya, Sriram Naresh, Manne Munikumar, Shilpa S Shetty, Pradeep Nataranjan, Suchetha Kumari N
Format: Article
Language:English
Published: SpringerOpen 2025-08-01
Series:Beni-Suef University Journal of Basic and Applied Sciences
Subjects:
Online Access:https://doi.org/10.1186/s43088-025-00668-0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849225984944898048
author Flama Monteiro
Vijith Vittal Shetty
Ranjitha Acharaya
Sriram Naresh
Manne Munikumar
Shilpa S Shetty
Pradeep Nataranjan
Suchetha Kumari N
author_facet Flama Monteiro
Vijith Vittal Shetty
Ranjitha Acharaya
Sriram Naresh
Manne Munikumar
Shilpa S Shetty
Pradeep Nataranjan
Suchetha Kumari N
author_sort Flama Monteiro
collection DOAJ
description Abstract Introduction An extensive array of medicinal plants has undergone investigation, underscoring the imperative for the continued screening of natural inhibitors with the potential to target cancer metabolism. The current research endeavor was directed toward evaluating the chemotherapeutic efficacy of peel extracts of Citrus maxima and its constituent flavonoid, Naringin (NA), in the context of breast cancer, specifically targeting the pyruvate kinase isozyme M2 (PKM2). Materials and methods Extracts from the peel of Citrus maxima were prepared and analyzed using liquid chromatography–mass spectrometry (LC–MS) to detect the presence of the bioactive compound, NA. The potential anti-proliferative effects of these peel extracts of Citrus maxima and NA were examined against human breast cancer cell lines utilizing an MTT assay. To investigate the distribution of the cell cycle, cell cycle analysis was conducted. The induction of apoptosis was ascertained using Annexin V-FITC through flow cytometry. The protein expression of PKM2 was analyzed using Western blotting. Molecular docking and dynamics simulations analysis were employed. Results Liquid chromatography–mass spectrometry (LC–MS) analysis confirmed the existence of NA within the extracts of Citrus maxima. Both the crude extracts and NA demonstrated a dose-dependent inhibition of breast cancer cell proliferation. Our findings indicate that these crude extracts and NA instigate both early and late apoptosis, in addition to causing cell cycle arrest in the G2/M phase. Immunoblotting studies further revealed that the expression of PKM2 protein was suppressed by both the crude extracts and NA. Computational analysis demonstrated stable binding affinity with Ser77, His78, and Lys207 of PKM2. Conclusion This investigation unveils the presence of NA within Citrus maxima extracts, exhibiting robust affinity for PKM2 via molecular docking and dynamics simulations. Extracts and NA dose-dependently inhibit breast cancer cell proliferation. Notably, PKM2 regulates cancer cell glycolysis, promising intricate therapeutic prospects for breast cancer.
format Article
id doaj-art-5addcb205aa9446da3c211cd80a41fb4
institution Kabale University
issn 2314-8543
language English
publishDate 2025-08-01
publisher SpringerOpen
record_format Article
series Beni-Suef University Journal of Basic and Applied Sciences
spelling doaj-art-5addcb205aa9446da3c211cd80a41fb42025-08-24T11:45:32ZengSpringerOpenBeni-Suef University Journal of Basic and Applied Sciences2314-85432025-08-0114111710.1186/s43088-025-00668-0Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibitionFlama Monteiro0Vijith Vittal Shetty1Ranjitha Acharaya2Sriram Naresh3Manne Munikumar4Shilpa S Shetty5Pradeep Nataranjan6Suchetha Kumari N7Department of Biochemistry, MGM Medical College Panvel, Mahatma Gandhi Mission Institute of Health SciencesDepartment of Oncology, KS Hegde Medical Academy, Nitte (Deemed to be University)Department of Biochemistry, KS Hegde Medical Academy, Nitte (Deemed to be University)SSPM Medical College and Lifetime hospitalDepartment of Bioinformatics, Manna Biotech Private LimitedCentral Research Laboratory, KS Hegde Medical Academy, Nitte (Deemed to be University)Department of Biotechnology, Bioinformatics Centre, Anna UniversityDepartment of Biochemistry, KS Hegde Medical Academy, Nitte (Deemed to be University)Abstract Introduction An extensive array of medicinal plants has undergone investigation, underscoring the imperative for the continued screening of natural inhibitors with the potential to target cancer metabolism. The current research endeavor was directed toward evaluating the chemotherapeutic efficacy of peel extracts of Citrus maxima and its constituent flavonoid, Naringin (NA), in the context of breast cancer, specifically targeting the pyruvate kinase isozyme M2 (PKM2). Materials and methods Extracts from the peel of Citrus maxima were prepared and analyzed using liquid chromatography–mass spectrometry (LC–MS) to detect the presence of the bioactive compound, NA. The potential anti-proliferative effects of these peel extracts of Citrus maxima and NA were examined against human breast cancer cell lines utilizing an MTT assay. To investigate the distribution of the cell cycle, cell cycle analysis was conducted. The induction of apoptosis was ascertained using Annexin V-FITC through flow cytometry. The protein expression of PKM2 was analyzed using Western blotting. Molecular docking and dynamics simulations analysis were employed. Results Liquid chromatography–mass spectrometry (LC–MS) analysis confirmed the existence of NA within the extracts of Citrus maxima. Both the crude extracts and NA demonstrated a dose-dependent inhibition of breast cancer cell proliferation. Our findings indicate that these crude extracts and NA instigate both early and late apoptosis, in addition to causing cell cycle arrest in the G2/M phase. Immunoblotting studies further revealed that the expression of PKM2 protein was suppressed by both the crude extracts and NA. Computational analysis demonstrated stable binding affinity with Ser77, His78, and Lys207 of PKM2. Conclusion This investigation unveils the presence of NA within Citrus maxima extracts, exhibiting robust affinity for PKM2 via molecular docking and dynamics simulations. Extracts and NA dose-dependently inhibit breast cancer cell proliferation. Notably, PKM2 regulates cancer cell glycolysis, promising intricate therapeutic prospects for breast cancer.https://doi.org/10.1186/s43088-025-00668-0Citrus maxima peel extractPKM2NaringinBreast cancerLC–MSMolecular docking
spellingShingle Flama Monteiro
Vijith Vittal Shetty
Ranjitha Acharaya
Sriram Naresh
Manne Munikumar
Shilpa S Shetty
Pradeep Nataranjan
Suchetha Kumari N
Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
Beni-Suef University Journal of Basic and Applied Sciences
Citrus maxima peel extract
PKM2
Naringin
Breast cancer
LC–MS
Molecular docking
title Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
title_full Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
title_fullStr Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
title_full_unstemmed Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
title_short Naringin from Citrus maxima peel: a potential therapeutic agent for breast cancer via PKM2 inhibition
title_sort naringin from citrus maxima peel a potential therapeutic agent for breast cancer via pkm2 inhibition
topic Citrus maxima peel extract
PKM2
Naringin
Breast cancer
LC–MS
Molecular docking
url https://doi.org/10.1186/s43088-025-00668-0
work_keys_str_mv AT flamamonteiro naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT vijithvittalshetty naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT ranjithaacharaya naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT sriramnaresh naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT mannemunikumar naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT shilpasshetty naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT pradeepnataranjan naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition
AT suchethakumarin naringinfromcitrusmaximapeelapotentialtherapeuticagentforbreastcancerviapkm2inhibition